Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Nutritional Therapy and AGIs Improve Postprandial Glucose in Diabetes
Last updated June 15, 2026
Key finding
Postprandial mean glucose across meals was significantly lower with all active interventions compared with regular diet (p<0.05), with highest reduction observed with acarbose.
This study compared the effectiveness of nutritional therapy and alpha-glucosidase inhibitors in managing type 2 diabetes, finding significant reductions in glucose levels with both interventions.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effectiveness of nutritional therapy and alpha-glucosidase inhibitors in managing type 2 diabetes, finding significant reductions in glucose levels with both interventions.
Clinical relevance
These findings are significant as they suggest that both dietary changes and pharmaceutical options can effectively manage blood sugar levels in individuals with type 2 diabetes. This can help clinicians tailor treatment plans to improve patient outcomes and potentially reduce the risk of diabetes-related complications.
Keep in mind
Limited generalizability due to specific population characteristics. Potential confounding factors not fully controlled. Short duration of follow-up may not capture long-term effects.
Published in
Journal Reference
Publication details and source links for this paper.
Alexander M, John RA, Praveen RS, Anudeep G, Shivaraj SH. Comparative Effectiveness of Nutritional Therapy and Alpha-Glucosidase Inhibitors in Type 2 Diabetes Management. Cureus. 2026;18(4):e106557. doi:10.7759/cureus.106557
Main Effects
Postprandial mean glucose levels decreased by 2.5 mg/dL (p=0.001).
24-hour mean glucose levels decreased by 3 mg/dL (p=0.001).
The proportion of participants achieving target PPG (<180 mg/dl) increased by 50% (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Acarbose, Low glycemic index treatment (LGIT), Voglibose and 24-hour glucose, Glucose area under the curve (AUC), Mean amplitude of glycemic excursions (MAGE), and 2 more.
This study contributes evidence to
Primary intervention
Acarbose
Primary outcomes
- 24-hour glucose
- Glucose area under the curve (AUC)
- Mean amplitude of glycemic excursions (MAGE)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
14
Evidence pairs
14
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
14
Evidence pairs
655
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 14 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Alpha-glucosidase inhibitors and CGM Time in Range
Related evidence
Evidence relationship
Alpha-glucosidase inhibitors and Glucose Variability
Save evidence
Evidence relationship
Alpha-glucosidase inhibitors and Postprandial and OGTT Glucose
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Glucose area under the curve (AUC)
Acarbose → Glucose area under the curve (AUC)
Acarbose → Glucose area under the curve (AUC)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean amplitude of glycemic excursions (MAGE)
Acarbose → Mean amplitude of glycemic excursions (MAGE)
Acarbose → Mean amplitude of glycemic excursions (MAGE)
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerPostprandial blood glucose
Acarbose → Postprandial blood glucose
Acarbose → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial hypoglycemia incidence
Acarbose → Postprandial hypoglycemia incidence
Acarbose → Postprandial hypoglycemia incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker24-hour glucose
Low glycemic index treatment (LGIT) → 24-hour glucose
Low glycemic index treatment (LGIT) → 24-hour glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGlucose area under the curve (AUC)
Low glycemic index treatment (LGIT) → Glucose area under the curve (AUC)
Low glycemic index treatment (LGIT) → Glucose area under the curve (AUC)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean amplitude of glycemic excursions (MAGE)
Low glycemic index treatment (LGIT) → Mean amplitude of glycemic excursions (MAGE)
Low glycemic index treatment (LGIT) → Mean amplitude of glycemic excursions (MAGE)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial blood glucose
Low glycemic index treatment (LGIT) → Postprandial blood glucose
Low glycemic index treatment (LGIT) → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGlucose area under the curve (AUC)
Voglibose → Glucose area under the curve (AUC)
Voglibose → Glucose area under the curve (AUC)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean amplitude of glycemic excursions (MAGE)
Voglibose → Mean amplitude of glycemic excursions (MAGE)
Voglibose → Mean amplitude of glycemic excursions (MAGE)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial blood glucose
Voglibose → Postprandial blood glucose
Voglibose → Postprandial blood glucose
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial hypoglycemia incidence
Voglibose → Postprandial hypoglycemia incidence
Voglibose → Postprandial hypoglycemia incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Postprandial mean glucose significantly reduced with interventions.
- 24-hour mean glucose levels were notably lower, especially with acarbose.
- Higher proportion of participants reached target PPG levels with acarbose.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Individuals seeking dietary and pharmaceutical options for blood sugar management.
Keep in Mind
- Results may not apply to all demographics due to study population.
- Effectiveness may vary based on individual adherence to dietary changes.
- Further research needed to explore long-term outcomes and safety.
Between the Lines
- Limited generalizability due to specific population characteristics.
- Potential confounding factors not fully controlled.
- Short duration of follow-up may not capture long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Alpha-glucosidase inhibitors and Glucose Variability, Alpha-glucosidase inhibitors and CGM Time in Range.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Alpha-glucosidase inhibitors Evidence Hub
All studies on Alpha-glucosidase inhibitors
2 studies
intervention_hubContributes to Alpha-glucosidase inhibitors evidence base.
Glucose Variability Evidence Hub
All studies measuring Glucose Variability
2 studies
outcome_hubMeasures Glucose Variability as a key outcome.
CGM Time in Range Evidence Hub
All studies measuring CGM Time in Range
1 studies
outcome_hubMeasures CGM Time in Range as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Acarbose and Mean amplitude of glycemic excursions (MAGE)
Intervention: AcarboseOutcome: Mean amplitude of glycemic excursions (MAGE)
2 results
All studies on Acarbose and 24-hour glucose
Intervention: AcarboseOutcome: 24-hour glucose
1 results
All studies on Acarbose
Intervention: Acarbose
2 results
All studies measuring Mean amplitude of glycemic excursions (MAGE)
Outcome: Mean amplitude of glycemic excursions (MAGE)
2 results
All studies measuring 24-hour glucose
Outcome: 24-hour glucose
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Alpha-glucosidase inhibitors improve cgm time in range?
Strong Evidence
Alpha-glucosidase inhibitors may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
24-hour glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Alpha-glucosidase inhibitors improve glucose variability?
Strong Evidence
Alpha-glucosidase inhibitors may improve Glucose Variability.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Mean amplitude of glycemic excursions (MAGE)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Alpha-glucosidase inhibitors improve postprandial and ogtt glucose?
Moderate Evidence
Alpha-glucosidase inhibitors may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Glucose area under the curve (AUC)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Postprandial blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Glycemic Control Treatments improve cgm time in range?
Moderate Evidence
Glycemic Control Treatments appears to improve CGM Time in Range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
24-hour glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Carnosine shows little effect on cardiovascular outcomes in diabetesGlucose variability increases with age in type 2 diabetes patientsLow Glycemic Load Diet Improves Metabolic Profiles in Type 2 DiabetesOnline Low GI Diet Improves Diabetes ManagementAcarbose may improve glycemic variability compared to sitagliptin.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.